Michael A. Laffan, MD

Professor
Centre for Haematology, Imperial College London, London, UK

Professor Mike Laffan DM FRCP FRCPath.
Centre for Haematology, Imperial College London.
Mike Laffan is Professor of Haemostasis and Thrombosis in the Department of Haematology at Imperial College, London, UK, and Director of the Hammersmith Hospital Haemophilia Centre, London, UK. He trained in medicine at the University of Oxford, UK, and in haematology at the Hammersmith and Royal Free Hospitals in London. His principal research interest is the structure–function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation.
He has published extensively on haemostasis and edited the 12th edition of Practical Haematology. Professor Laffan also chaired the British Society for Haematology Task Force on Haemostasis and Thrombosis for six years and the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) von Willebrand disease working party until 2020. He is currently chair of the BSH Guidelines Executive.

Presentation(s):

• SOA 01.2 - The Functions of Post Translational Modifications of von Willebrand Factor

  Sunday, July 10, 2022
  8:20 AM – 8:40 AM

• OC 11.1 - Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and strength; results from a sub-study of the FEISTY trial

  Sunday, July 10, 2022
  10:45 AM – 11:00 AM

• LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, July 10, 2022
  3:15 PM – 3:30 PM

• OC 21.2 - Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• OC 22.1 - Angiopoietin-2 binds to Von Willebrand Factor within Endothelial Cells and after Release from Weibel Palade Bodies and mediates Von Willebrand Factor dependent angiogenesis

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM

• PB0007 - Post-partum Acquired Haemophilia A in the COVID era – building the case for Emicizumab?

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0187 - FIX binding to collagen IV generates thrombin via the intrinsic tenase

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0411 - Hydroxychloroquine as an adjunct treatment for patients with triple positive thrombotic antiphospholipid syndrome- a single centre experience

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• PB0823 - The rare VWF non-canonical splice-site variant, c.8155+6T>A, causes type 3 von Willebrand disease in homozygosity and results in perinuclear retention of VWF in endothelial cells

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1433 - Analysis of uncharacterised Von Willebrand's Disease causing mutations located in the D4 and C-domains: identification of a novel type 2A variant and gain-of-function VWF

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PT 13.4 - Insights From Real World Practice to Support Haemophilia B Patients

  Tuesday, July 12, 2022
  12:15 PM – 1:00 PM

• PT 13.1 - Are we Meeting the Needs of Patients With Haemophilia B

  Tuesday, July 12, 2022
  12:15 PM – 12:25 PM

• PT 13.3 - Closing

  Tuesday, July 12, 2022
  12:55 PM – 1:00 PM

• OC 61.2 - Thrombosis and major bleeding in patients with severe COVID-19 supported by extracorporeal membrane oxygenation (ECMO)- multicentre observational study in UK

  Tuesday, July 12, 2022
  3:00 PM – 3:15 PM